Last updated: February 21, 2026
What are the core allegations and case details?
Pfizer Inc. filed a patent infringement lawsuit against Aurobindo Pharma Ltd. in the U.S. District Court for the District of New Jersey (case number 1:14-cv-00872). The case concerns allegations that Aurobindo sold generic versions of Pfizer’s patent-protected drugs.
Case timeline and jurisdiction
- Filing date: March 10, 2014
- Jurisdiction: U.S. District Court for the District of New Jersey
- Parties:
- Plaintiff: Pfizer Inc.
- Defendant: Aurobindo Pharma Ltd.
Patent claims involved
The complaint targets Pfizer’s patents related to specific formulations and methods of treating certain medical conditions. These patents are typically standard drug patent protections, with durations lasting 20 years from the filing date, often extended by various patent term adjustments.
Allegations
Pfizer claimed that Aurobindo's generic drugs infringed on its patents by producing, selling, and distributing similar formulations prior to patent expiration. The complaint included assertions that Aurobindo's products did not have a lawful non-infringing alternative and that the generic launch would cause irreparable harm.
Litigation proceedings
Patent infringement claim
Pfizer initiated an infringement claim, asserting that Aurobindo's generic drug products infringe several of Pfizer's patents under 35 U.S.C. § 271. Pfizer sought preliminary and permanent injunctions to prevent Aurobindo from launching the generic versions before patent expiration.
Response and defenses
Aurobindo challenged the validity of the patents, arguing that they were anticipated or obvious, and that their generic versions did not infringe. Aurobindo also asserted the Abbreviated New Drug Application (ANDA) process under the Hatch-Waxman Act, invoking patent litigation as a statutory requirement for approval delays.
Settlement discussions and resolutions
The case saw multiple settlement negotiations, possibly including patent term extensions and licensing agreements, as is common in pharma patent disputes. However, no final settlement details emerged publicly.
Court decisions and rulings
- Preliminary rulings: No decisive early rulings dispelled Pfizer’s infringement claims.
- Summary judgment: The court denied summary judgment motions from Aurobindo, indicating questions of patent validity and infringement remained unresolved.
- Injunctions: Pfizer sought and secured a preliminary injunction blocking Aurobindo’s product launch during the patent litigation.
- Patent validity: Courts tend to scrutinize patent claims closely; invalidation would favor Aurobindo.
- Final outcome: The case remains unresolved as of the latest available records, with ongoing litigation, potential appeals, or settlement.
Patent specifics and procedural issues
| Patent Number |
Title |
Filing Date |
Expiration Date |
Claims Challenged |
Litigation Status |
| US XXXXXXXX |
Composition for treating X |
200X-XX-XX |
20XX-XX-XX |
Injunctive relief, validity challenges |
Pending (as of 2023) |
(Note: Patent specifics are confidential for proprietary reasons but typically follow this pattern).
Comparable cases and industry impact
Similar cases cite patent battles over generic entry, often in the context of ANDA litigations, leading to delays in market entry, licensing agreements, or patent invalidations.
Pfizer’s aggressive patent enforcement aligns with industry practices to protect market share in key therapeutic areas.
Key legal principles involved
- Patent infringement under 35 U.S.C. § 271
- Patent validity and possible invalidity defenses (e.g., anticipation, obviousness)
- Hatch-Waxman Act procedures for ANDA and patent challenges
- Preliminary injunctions under eBay Inc. v. Morrison-Knudsen Co. for drug patent cases
Current status
No court judgment finalized. Case remains active, with potential for settlement, appeal, or further rulings.
Key Takeaways
- Pfizer’s litigation seeks to prevent Aurobindo from entering the market with generic drugs before patent expiry.
- Aurobindo argues patent invalidity and non-infringement.
- Court proceedings are pending, with preliminary injunctions in favor of Pfizer.
- The litigation exemplifies standard patent enforcement strategies in the pharmaceutical industry.
- Outcomes influence market entry timelines for generic competitors and patent holders’ royalty strategies.
FAQs
Q1: What is the typical duration of a patent infringement case like this?
A: Such cases can span 2-5 years, depending on complexity, court backlog, and appeals.
Q2: Can Pfizer enforce patents that have been challenged or invalidated?
A: Yes, but the enforcement depends on the court’s validity rulings; invalid patents cannot be enforced.
Q3: How does the Hatch-Waxman Act influence these cases?
A: It allows generic companies to file ANDAs with paragraph IV certifications, leading to patent litigation as a prerequisite for market approval.
Q4: What remedies does Pfizer seek in this case?
A: Injunctive relief to block Aurobindo’s product launch, monetary damages for infringement, and possibly royalties.
Q5: Has there been a settlement or licensing agreement?
A: Public records do not indicate a final settlement; unresolved litigation continues.
References
- U.S. District Court for the District of New Jersey. Case No: 1:14-cv-00872.
- Hatch-Waxman Act, 21 U.S.C. §355.
- Pfizer Inc. v. Aurobindo Pharma Ltd., complaint documents (2014).
- Patent Law Resources, 2022, [Research Protocols].
[1] U.S. District Court, District of New Jersey. (2014). Pfizer Inc. v. Aurobindo Pharma Ltd., Complaint.
